Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Factor Analysis of the BDI-II and HAMD-21 in Patients With Irritable Bowel Syndrome

View through CrossRef
Objective: The factorial validity of the Beck Depression Inventory-II (BDI-II) and the 21-item Hamilton Depression Rating Scale (HAMD-21) in individuals with Irritable Bowel Syndrome (IBS) has not yet been investigated. This study aimed to assess the factor structure of these instruments and analyze their interrelationships within the Georgian IBS population. Methods: Principal component analysis was performed on data from 89 IBS patients. Factors were determined using eigenvalues ≥1, with factor loadings exceeding 0.4 and oblique rotations identifying factor compositions. The Kaiser-Meyer-Olkin measure, Cronbach’s alpha, Bartlett’s test, communality, non-redundant residuals, and the component correlation matrix were used to assess factor validity. Intercorrelations between the scales’ symptoms were also analyzed. Results: The mean BDI-II score was 24.31 (standard deviation (SD) = 14.93) and the mean HAMD-21 score was 17.38 (SD = 8.91). According to the cutoff criteria for both scales, the sample exhibited moderate depression. The BDI-II identified three factors, while the HAMD-21 revealed four distinct factors. Combined analysis showed that most BDI-II items and core depressive symptoms from HAMD-21 clustered into Component I. Component II included four HAMD-21 items: insomnia (delayed), agitation, somatic anxiety, and insight. Significant positive correlations between paired BDI-II and HAMD-21 symptoms were found, with a high correlation (r = 0.88, p = 0.000) between the scales, differing from previous findings. Conclusion: The high correlations within components, along with low non-redundant residuals and high communality, indicate satisfactory factor validity for both the BDI-II and HAMD-21. The self-report BDI-II inventory and the HAMD-21 scale are complementary in evaluating depressive symptoms in patients with IBS.
Title: Factor Analysis of the BDI-II and HAMD-21 in Patients With Irritable Bowel Syndrome
Description:
Objective: The factorial validity of the Beck Depression Inventory-II (BDI-II) and the 21-item Hamilton Depression Rating Scale (HAMD-21) in individuals with Irritable Bowel Syndrome (IBS) has not yet been investigated.
This study aimed to assess the factor structure of these instruments and analyze their interrelationships within the Georgian IBS population.
Methods: Principal component analysis was performed on data from 89 IBS patients.
Factors were determined using eigenvalues ≥1, with factor loadings exceeding 0.
4 and oblique rotations identifying factor compositions.
The Kaiser-Meyer-Olkin measure, Cronbach’s alpha, Bartlett’s test, communality, non-redundant residuals, and the component correlation matrix were used to assess factor validity.
Intercorrelations between the scales’ symptoms were also analyzed.
Results: The mean BDI-II score was 24.
31 (standard deviation (SD) = 14.
93) and the mean HAMD-21 score was 17.
38 (SD = 8.
91).
According to the cutoff criteria for both scales, the sample exhibited moderate depression.
The BDI-II identified three factors, while the HAMD-21 revealed four distinct factors.
Combined analysis showed that most BDI-II items and core depressive symptoms from HAMD-21 clustered into Component I.
Component II included four HAMD-21 items: insomnia (delayed), agitation, somatic anxiety, and insight.
Significant positive correlations between paired BDI-II and HAMD-21 symptoms were found, with a high correlation (r = 0.
88, p = 0.
000) between the scales, differing from previous findings.
Conclusion: The high correlations within components, along with low non-redundant residuals and high communality, indicate satisfactory factor validity for both the BDI-II and HAMD-21.
The self-report BDI-II inventory and the HAMD-21 scale are complementary in evaluating depressive symptoms in patients with IBS.

Related Results

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine
CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inf...
Irritable bowel syndrome with constipation: issues of pathogenesis, diagnostics and treatment
Irritable bowel syndrome with constipation: issues of pathogenesis, diagnostics and treatment
Issues related to the diagnosis and treatment of irritable bowel syndrome occupy one of the central places in gastroenterology, due to the fact that in recent years there has been ...
Role du fructose dans la physiopathologie du syndrome de l'intestin irritable
Role du fructose dans la physiopathologie du syndrome de l'intestin irritable
.La consommation journalière de fructose est en augmentation croissante, jusqu'à plus de 50g par jour aux Etats-Unis et en Europe de l'Ouest. Le fructose est de plus en plus incorp...
ANALISIS PERTIMBANGAN MAHKAMAH AGUNG DALAM MENGABULKAN KASASI TERDAKWA (STUDI PUTUSAN NOMOR 2959/K/PID.SUS/2022)
ANALISIS PERTIMBANGAN MAHKAMAH AGUNG DALAM MENGABULKAN KASASI TERDAKWA (STUDI PUTUSAN NOMOR 2959/K/PID.SUS/2022)
<p><em><span class="markedContent"><span style="left: calc(var(--scale-factor)*195.53px); top: calc(var(--scale-factor)*496.87px); font-size: calc(var(--scale-...
Efficacy and Safety of Probiotic versus Conventional Treatment of Irritable Bowel Syndrome
Efficacy and Safety of Probiotic versus Conventional Treatment of Irritable Bowel Syndrome
Abstract Background Irritable bowel syndrome is a gastrointestinal syndrome characterized by chronic abdominal pain and a...

Back to Top